Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 2 of about 2   

Articles published

DVAX 14.29 -0.22 (-1.52%)
price chart
3 Vaccine Companies With Upcoming Catalysts
Dynavax Technologies Corporation (NASDAQ:DVAX), a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
Related articles »  
Andrew Gengos out, John Walker in as Neuraltus CEO
KAI was bought by Amgen Inc. this year for $412 million, Novacea merged with Transcept Pharmaceuticals Inc. in early 2009, and Renovis merged with Evotec AG in 2008.